Prenatal Dex Study
A legfontosabb adatok
- Ki végzi
- Hospices Civils de Lyon
- Hol
- Franciaország10 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 354 fő vett részt
- Kezdés
- 2016. okt. 4.
- Befejezés
- 2025. jún. 13.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Neuropsychological and cognitive assessment
- A regiszteradat frissítve
- 2025. december 11.
Ki vehet részt
- Életkor
- 6 év – 15 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Groups D+1, D+2, D-1 and D-2
- Male or female
- Patient with Congenital Adrenal Hyperplasia or sibling of a CAH patient
- Age: 6 to 15 years (at the time of inclusion)
- The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
- Subject with health insurance; Group D-3 (Schoolchildren)
- Male or female
- With no connection with Congenital Adrenal Hyperplasia
- Age: 6 to 15 years (at the time of inclusion)
- The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
- Subject with health insurance
Ki nem vehet részt
- Patient/Subject whose mother has received another treatment during her pregnancy with possible known adverse events on the neuropsychological development of the child
- Patient/Subject with another genetic disease
- Patient/Subject with known neuropsychology disease(s)
- For all groups :
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The classic form of 21-hydroxylase deficiency (prevalence 1/15,000) is the most common cause of congenital adrenal hyperplasia (CAH). This autosomic recessive disease is responsible for virilization of the external genitalia in girls through androgen hypersecretion during fetal life. Since 1984, the Lyon Pediatric Endocrinology group has proposed prenatal dexamethasone (DEX) for all fetuses at risk of CAH With the aim of preventing fetal androgen hypersecretion in affected girls and avoiding poor long-term results from reconstructive surgery. Prenatal DEX was used in Europe and the USA but its use was recently suspended: in 2007, a Swedish study conducted on 26 children treated with DEX in utero for a short period of time reported cognitive impairments. These data were not confirmed by an American study on the short-term DEX use, which showed potential cognitive impairments in CAH children exposed to DEX for long periods of time. These confusing and controversial results have caused the scientific community to question its position and have resulted in the suspension of the use of prenatal DEX with drastic consequences for CAH girls (virilization; genital surgery etc.). In this context, an evaluation of neuropsychological development under in utero DEX is essential to validate its indication for use during the prenatal period. This study will evaluate outcomes using prospective cognitive and emotional assessments. It will first focus on the unaffected children previously treated in utero in order to assess the adverse effects of the drug. The study will then assess the children with CAH for whom DEX could have beneficial effects.
A vizsgálat 5 csoportja
- Group D+ 1A vizsgált kezelés
Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.
Kezelés: Neuropsychological and cognitive assessment
- Group D+ 2A vizsgált kezelés
Girls and boys affected by CAH and treated in utero by Dexamethasone.
Kezelés: Neuropsychological and cognitive assessment
- : Group D - 1Már használt kezelés, összehasonlításként
Girls and boys not affected by CAH and not treated in utero by Dexamethasone.
Kezelés: Neuropsychological and cognitive assessment
- Group D - 2Már használt kezelés, összehasonlításként
Girls and boys affected by CAH and not treated in utero by Dexamethasone.
Kezelés: Neuropsychological and cognitive assessment
- Group D - 3Egyéb csoport
Girls and boys enrolled in school closed to Lyon
Kezelés: Neuropsychological and cognitive assessment
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Multicentric Evaluation of in Utero Dexamethasone (DEX) on the Cognitive Development of Children at Risk of Congenital Adrenal Hyperplasia
- A regiszteradat frissítve
- 2025. december 11.